Evidence map›Paper›PMID 28743866›Full record

ArticleScientific reports2017

Mass Spectrometry Imaging proves differential absorption profiles of well-characterised permeability markers along the crypt-villus axis.

Anna Nilsson, Alexandra Peric, Marie Strimfors, Richard J A Goodwin, Martin A Hayes, Per E Andrén, Constanze Hilgendorf

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
1.8field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 25 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Article
  6. Review
  7. Review
  8. Article
  9. Review
  10. Review
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 5 countries.

Anna NilssonScience for Life Laboratory, Biomolecular Imaging and Proteomics, National Resource for Mass Spectrometry Imaging, Department of Pharmaceutical Biosciences, Uppsala University, Uppsala, Sweden.
Alexandra PericCardiovascular and Metabolic Diseases, Innovative Medicines and Early Development, AstraZeneca Gothenburg, Gothenburg, Sweden.
Marie StrimforsCardiovascular and Metabolic Diseases, Innovative Medicines and Early Development, AstraZeneca Gothenburg, Gothenburg, Sweden.
Richard J A GoodwinMass Spectrometry Imaging, Drug Safety and Metabolism, Innovative Medicines and Early Development, AstraZeneca Cambridge, Cambridge, United Kingdom.
Martin A HayesCardiovascular and Metabolic Diseases, Innovative Medicines and Early Development, AstraZeneca Gothenburg, Gothenburg, Sweden.ORCID 0000-0002-2640-8464
Per E AndrénScience for Life Laboratory, Biomolecular Imaging and Proteomics, National Resource for Mass Spectrometry Imaging, Department of Pharmaceutical Biosciences, Uppsala University, Uppsala, Sweden.ORCID 0000-0002-4062-7743
Constanze HilgendorfCardiovascular and Metabolic Diseases, Innovative Medicines and Early Development, AstraZeneca Gothenburg, Gothenburg, Sweden. Constanze.hilgendorf@astrazeneca.com.
AstraZeneca (Sweden) · SEUppsala University · SEAstraZeneca (Netherlands) · NLAstraZeneca (United Kingdom) · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Knowledge about the region-specific absorption profiles from the gastrointestinal tract of orally administered drugs is a critical factor guiding dosage form selection in drug development. We have used a novel approach to study three well-characterized permeability and absorption marker drugs in the intestine. Propranolol and metoprolol (highly permeable compounds) and atenolol (low-moderate permeability compound) were orally co-administered to rats. The site of drug absorption was revealed by high spatial resolution matrix-assisted laser desorption ionization mass spectrometry imaging (MALDI-MSI) and complemented by quantitative measurement of drug concentration in tissue homogenates. MALDI-MSI identified endogenous molecular markers that illustrated the villi structures and confirmed the different absorption sites assigned to histological landmarks for the three drugs. Propranolol and metoprolol showed a rapid absorption and shorter transit distance in contrast to atenolol, which was absorbed more slowly from more distal sites. This study provides novel insights into site specific absorption for each of the compounds along the crypt-villus axis, as well as confirming a proximal-distal absorption gradient along the intestine. The combined analytical approach allowed the quantification and spatial resolution of drug distribution in the intestine and provided experimental evidence for the suggested absorption behaviour of low and highly permeable compounds.

Indexed as

Administration, OralAnimalsAntihypertensive AgentsAtenololIntestinal AbsorptionIntestinesMaleMetoprololPropranololRatsSpectrometry, Mass, Matrix-Assisted Laser Desorption-IonizationAntihypertensive AgentsAtenololMetoprololPropranolol

Identifiers

PMID28743866
PMCPMC5526999
OpenAlexW2739425851

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.